HemoGenyx Pharmaceuticals Plc (GB:HEMO) has released an update.
HemoGenyx Pharmaceuticals has secured a strategic investment of $350,000 from Prevail Partners, LLC to support the upcoming Phase I pediatric clinical study for its innovative CAR-T cell therapy targeting acute myeloid leukemia (AML) and a subset of acute lymphoblastic leukemia (ALL) in children. The partnership will also utilize Prevail InfoWorks’ expertise as a Clinical Research Organization to ensure efficient trial execution and real-time data analysis. This investment, at a significant premium to the current share price, underlines investor confidence in HemoGenyx’s potential to advance treatment for these life-threatening diseases.
For further insights into GB:HEMO stock, check out TipRanks’ Stock Analysis page.
